BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

May 12, 2016 7:00 AM UTC

Mouse studies suggest inhibiting TNFRSF1A or RIPK3 could help treat colon and other cancers harboring loss-of-function HACE1 mutations. In a mouse model of HACE1-mutant colon cancer, systemic knockout of TNFRSF1A or RIPK3 decreased tumor growth, weight loss and diarrhea and other colonic pathology compared with normal expression of TNFRSF1A and RIPK3. Next steps include testing inhibition of TNFRSF1A or RIPK3 in models of other HACE1-mutant cancers.

GlaxoSmithKline plc has two anti-TNFRSF1A antibodies, 2862277 and 1995057, in Phase II and Phase I testing, respectively, to treat acute lung injury. ...